Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...

(Reuters) -Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, aiming ...

U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on ...

Eli Lilly, Home Depot, SAP and NRP highlight key themes in pharma, retail, cloud growth???and energy sector challenges.

Eli Lilly’s (NYSE:LLY) experimental obesity therapy eloralintide has caused up to 11% weight loss over 12 weeks in an ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

As part of the deal, Eli Lilly would pay almost $1bn upfront for Verve, which is developing a gene-editing therapy to treat bad cholesterol, and a further $300mn based on the biotech company achieving ...

Eli Lilly and Company (NYSE: LLY) is one of the 17 stocks that Jim Cramer commented on. Cramer showed a positive sentiment ...

Eli Lilly and Company ( NYSE: LLY) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director of Investor ...